APP Pharmaceuticals expands Methotrexate Injection supply
The company has also filled 10,000 vials of preservative-free Methotrexate Injection, USP, which should be available to clinicians shortly. A further 10,000 vials have been filled and the
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.